William D.  Mccombe net worth and biography

William Mccombe Biography and Net Worth

William (Bill) McCombe joined Cytek in March 2024 as our Chief Financial Officer. Prior to joining our company, Bill served as Chief Financial Officer at Velo3D, a leader in metal 3D printing systems, from 2020 to 2023; as Chief Financial Officer at HZO, a leader in delivering protective nano coatings for electronics, from 2018 to 2020; and as Chief Financial Officer at Maxar Technologies, a multi-billion-dollar revenue satellite and space imaging company, from 2016 to 2018.  Bill also has over 20 years of experience in investment banking having served as Managing Director, Mergers and Acquisitions, at Bank of America Merrill Lynch and Morgan Stanley.

Bill holds an M.B.A. degree from Columbia University Graduate School of Business and a Bachelor of Laws and Commerce from the University of Melbourne.

What is William D. Mccombe's net worth?

The estimated net worth of William D. Mccombe is at least $289.88 thousand as of June 2nd, 2025. Mccombe owns 55,746 shares of Cytek Biosciences stock worth more than $289,879 as of December 5th. This net worth evaluation does not reflect any other assets that Mccombe may own. Learn More about William D. Mccombe's net worth.

How do I contact William D. Mccombe?

The corporate mailing address for Mccombe and other Cytek Biosciences executives is , , . Cytek Biosciences can also be reached via phone at 877-922-9835 and via email at [email protected]. Learn More on William D. Mccombe's contact information.

Has William D. Mccombe been buying or selling shares of Cytek Biosciences?

William D. Mccombe has not been actively trading shares of Cytek Biosciences during the last ninety days. Most recently, on Monday, June 2nd, William D. Mccombe bought 35,000 shares of Cytek Biosciences stock. The stock was acquired at an average cost of $2.78 per share, with a total value of $97,300.00. Following the completion of the transaction, the chief financial officer now directly owns 55,746 shares of the company's stock, valued at $154,973.88. Learn More on William D. Mccombe's trading history.

Who are Cytek Biosciences' active insiders?

Cytek Biosciences' insider roster includes Patrik Jeanmonod (CFO), Wenbin Jiang (CEO), William Mccombe (CFO), and Ming Yan (CTO). Learn More on Cytek Biosciences' active insiders.

Are insiders buying or selling shares of Cytek Biosciences?

During the last year, Cytek Biosciences insiders bought shares 2 times. They purchased a total of 70,000 shares worth more than $194,600.00. The most recent insider tranaction occured on June, 2nd when CFO William D Mccombe bought 35,000 shares worth more than $97,300.00. Insiders at Cytek Biosciences own 10.3% of the company. Learn More about insider trades at Cytek Biosciences.

Information on this page was last updated on 6/2/2025.

William D. Mccombe Insider Trading History at Cytek Biosciences

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/2/2025Buy35,000$2.78$97,300.0055,746View SEC Filing Icon  
6/2/2025Buy35,000$2.78$97,300.0055,746View SEC Filing Icon  
See Full Table

William D. Mccombe Buying and Selling Activity at Cytek Biosciences

This chart shows William D Mccombe's buying and selling at Cytek Biosciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Cytek Biosciences Company Overview

Cytek Biosciences logo
Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems. The company also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, an automated loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in European, Latin American, and the Middle Eastern countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.
Read More

Today's Range

Now: $5.20
Low: $4.96
High: $5.37

50 Day Range

MA: $4.49
Low: $3.38
High: $5.88

2 Week Range

Now: $5.20
Low: $2.37
High: $7.30

Volume

1,073,370 shs

Average Volume

1,828,866 shs

Market Capitalization

$664.87 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.29